(Q38060571)

28 August 2017

1 reference

title

CSF penetration by antiretroviral drugs (English)

1 reference

28 August 2017

main subject

anti-retroviral agent

0 references

author name string

Christine Eisfeld

1

1 reference

28 August 2017

Doris Reichelt

2

1 reference

28 August 2017

Stefan Evers

3

1 reference

28 August 2017

Ingo Husstedt

4

1 reference

28 August 2017

publication date

1 January 2013

1 reference

28 August 2017

number of pages

25

1 reference

inferred from page(s)

published in

CNS Drugs

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

31-55

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-012-0018-x

28 August 2017

exact match

0 references

cites work

Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Changing incidence of central nervous system diseases in the EuroSIDA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Factors affecting delivery of antiviral drugs to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Stavudine entry into cerebrospinal fluid after single and multiple doses in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Etravirine concentrations in CSF in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Indinavir in cerebrospinal fluid of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Low atazanavir concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Therapeutic amprenavir concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

A review of the pharmacokinetics of abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Neuropsychiatric complications of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Neuroimaging correlates of HIV-associated BBB compromise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Antiretroviral drugs and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Microdialysis in the study of drug transporters in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Zidovudine serum, cerebrospinal fluid, and brain concentrations following chronic administration of a new zidovudine formulation via an implantable pump in dogs [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Effect of age on distribution of zidovudine (azidothymidine) into the cerebrospinal fluid of Macaca nemestrina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

The transport of the anti-HIV drug, 2',3'-didehydro-3'-deoxythymidine (D4T), across the blood-brain and blood-cerebrospinal fluid barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Microdialysis evaluation of the brain distribution of stavudine following intranasal and intravenous administration to rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Neurocognitive dysfunction in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

HIV and age do not substantially interact in HIV-associated neurocognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

HIV, the brain, children, HAART and 'neuro-HAART': a complex mix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Lopinavir with Ritonavir Reduces the HIV RNA Level in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0018-X

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

21 January 2018

1 reference

12 December 2020

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

1 reference

12 December 2020

Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial

1 reference

12 December 2020

Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir

1 reference

12 December 2020

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin

1 reference

12 December 2020

Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy

1 reference

12 December 2020

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates

1 reference

12 December 2020

Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection

1 reference

12 December 2020

Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit

1 reference

12 December 2020

HIV-associated neurocognitive disease continues in the antiretroviral era.

1 reference

12 December 2020

Pharmacokinetics and extracellular distribution to blood, brain, and muscle of alovudine (3'-fluorothymidine) and zidovudine in the rat studied by microdialysis.

1 reference

12 December 2020

Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid

1 reference

12 December 2020

Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients

1 reference

12 December 2020

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma

1 reference

12 December 2020

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

1 reference

12 December 2020

Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis.

1 reference

12 December 2020

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

1 reference

12 December 2020

Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients

1 reference

12 December 2020

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir

1 reference

12 December 2020

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment

1 reference

12 December 2020

Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina

1 reference

12 December 2020

Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system

1 reference

12 December 2020

Independent HIV replication in paired CSF and blood viral isolates during antiretroviral therapy

1 reference

12 December 2020

The pharmacokinetics of zidovudine administered by continuous infusion in children

1 reference

12 December 2020

In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.

1 reference

12 December 2020

Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT)

1 reference

12 December 2020

Highly active antiretroviral therapy improves neurocognitive functioning

1 reference

12 December 2020

Neurologic complications of HIV disease and their treatment

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020

Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.

1 reference

12 December 2020

Evaluation of a brain-targeting zidovudine chemical delivery system in dogs

1 reference

12 December 2020

Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid

1 reference

12 December 2020

Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

1 reference

12 December 2020

Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)

1 reference

12 December 2020

10.1007/S40263-012-0018-X

Identifiers

DOI

1 reference

28 August 2017

1 reference